Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perampanel in Glioma-refractory Epilepsy
NCT03636958Withdrawn
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Feb 2021
- Primary completion
- Jul 2025
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of perampanel in epilepsy (2 arms), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoints: Decrease of the monthly frequency of crisis at 23 weeks, Numbers of crisis at baseline at 6 weeks and 1 more. Planned start Feb 2021; status: withdrawn.
02
Drugs
perampanel
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT03636958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03636958.